First Look: Debut of Roadshow Project List at the 2023 Future Healthcare Equity Investment Forum!

Full name of the company:Hangzhou V-Onco Medical Technology Co., Ltd.

Roadshow Project Name:Focus on Minimally Invasive Tumor Ablation Solutions

Roadshow Project Introduction:Hangzhou V-Onco Medical Technology Co., Ltd.'s core technology, the "Micro-Nano Knife" (SIRE), has achieved a breakthrough in performing single-needle IRE tumor ablation under local anesthesia. The "Micro-Nano Knife" holds a principle-level patent for waveform energy in the field of irreversible electroporation (IRE) tissue. Since 2000, the company's technical team has been the first in the world to propose the new concept of using irreversible electroporation (IRE) for cancer treatment and has subsequently developed three generations of irreversible electroporation technologies. The company focuses on the field of minimally invasive tumor treatment, expanding the application of the Micro-Nano Knife through multimodal approaches combined with systemic comprehensive methods such as chemotherapy and immunotherapy, providing minimally invasive solutions for cancer treatment.

Full name of the company:Hangzhou Shudan Medical Technology Co., Ltd.

Roadshow Project Name:Using Intelligent Technology to Safeguard Global Brain Health

Project Introduction for Roadshow:With the accelerating trend of population aging, the number of patients with cognitive impairment is increasing year by year. It is estimated that by 2050, this figure will rise to 152 million. However, there is currently a lack of effective intervention methods, representing a significant unmet medical need. Based on the understanding of Gamma neural oscillations, the Shudan Medical team has developed the first non-invasive sensory stimulation smart home device in China for AD-induced dementia, which intervenes in abnormal oscillations under pathological conditions through physical therapy, aiming to halt or even reverse the decline in brain function. So far, Shudan Medical's products have completed validation for both efficacy and safety in both healthy and patient populations and have established collaborations with multiple hospitals, rehabilitation institutions, and more across various regions.

Full name of the company:Hangzhou KNOTRIX Information Technology Co., Ltd.

Roadshow Project Name:KNOTRIX New Media Health Ecosystem Operation

Project Introduction for Roadshow:KNOTRIX was founded in 2020, headquartered in Hangzhou, China, with the original mission of "making health accessible to all." It focuses on building a new media health content ecosystem, providing users with authentic and effective health knowledge, products, and services through high-quality content creation, precise fan services, rapid product iteration, and AI technology support. KNOTRIX deeply serves over 100 medical & healthcare IPs, with total fans across all platforms exceeding 35 million, annual views nearing 10 billion, more than 150,000 precisely targeted private domain fans, and an annual GMV of approximately 1 billion yuan.

Full name of the company:Beijing OriginGene-tech Biotechnology Co., Ltd.

Roadshow Project Name:Innovative Platform for Microfluidic Electrochemical Detection

Project Introduction for Roadshow:Beijing OriginGene-tech Biotechnology Co., Ltd. is a high-tech company that integrates the research and development, production, sales of in vitro diagnostic reagents and supporting equipment, as well as medical testing services. It has been honored with titles such as National High-tech Enterprise, "Specialized, Precise, Unique and Innovative" Small and Medium-sized Enterprise, National Science and Technology Small and Medium-sized Enterprise, Zhongguan Village High-tech Enterprise, Zhongguan Village Golden Seed Enterprise, and Beijing Intellectual Property Pilot Unit. As the first supplier of microfluidic electrochemical detection platforms in China, it covers application needs in nucleic acids, immunity, and biochemistry, providing OEM and CDMO services for various IVD enterprises, as well as scientific research and achievement transformation in electrochemical biosensing for universities and research institutes. Investment highlights: high technical barriers, obvious first-mover advantage, and great market potential.

Full name of the enterprise:Resproly

Roadshow Project Name:Resproly Inhalation Formulation Development and Commercialization Project

Introduction to the Roadshow Project:Resproly, founded by Dr. Yongqi Chen, a returning scientist, is dedicated to the research, production, and sales of inhalation formulation technologies for treating lung diseases. The founder has successfully developed 14 inhalation formulations. The company has cumulatively secured over 300 million yuan in investments from more than ten market-oriented investment institutions, including Qianhai Ark.

Resproly is the only innovative enterprise in China that has broken through all technical barriers in blister-type (represented by Seretide, with peak sales exceeding 5 billion USD), reservoir-type (represented by Symbicort, with peak sales exceeding 5 billion USD), and capsule-type (represented by Seebri, with peak sales of 600 million USD) drug delivery systems.

The company has a full staff, strong R&D capabilities, and comprehensive equipment. Three generic drugs have entered the clinical stage and will be the first generics to be launched in China in 2025. Two new drugs will initiate Phase I clinical trials overseas within 2023 and are expected to be approved for marketing by 2027.

Full name of the company:Shenzhen AoneMed Medical Technology Co., Ltd.

Roadshow Project Name:Omics Data Innovation for Precision Diagnosis and Treatment

Project Introduction for Roadshow:AoneMed is the first specialized and innovative enterprise in China focusing on metabolomics and genomics. In the IVD sector, the company has established intelligent manufacturing bases with GMP facilities exceeding 4,000 square meters in Shenzhen and Xuzhou, achieving the localization of imported equipment. It offers the highest cost-performance and most sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS), serving over 100 top-tier tertiary hospitals across China with equipment and reagents. In the ICL sector, the company operates three independent medical laboratories in Shenzhen, Shenyang, and Xuzhou, along with 12 city-level regional medical testing centers. AoneMed holds nearly a 90% market share of GC-MS in China, independently developed methodologies for newborn genetic metabolic disease screening and diagnosis, and actively participated in designing the inter-laboratory quality assessment programs led by China's National Health Commission.（NCCL-E-25）, formulate national standards. AoneMed will always innovate precision diagnosis and treatment through omics data, jointly promote the benefits of omics for humanity, and use technology to safeguard human life and health.

Full name of the enterprise:Jingchuang High Dimension Technology (Chengdu) Co., Ltd.

Roadshow Project Name:TCM Intelligent Tongue Diagnosis Instrument

Project Introduction for Roadshow:"Intelligent TCM Tongue Diagnosis Instrument" is a smart product that combines software and hardware, obtaining multiple invention patents and being selected for a project by China's Ministry of Industry and Information Technology. It has established 15 clinical sub-centers across Sichuan Province and conducted nearly seven months of clinical research in over 30 hospitals nationwide. Cases are diagnosed and labeled by TCM practitioners at the associate chief level or above. The instrument features high-precision image positioning guidance and recognition, advanced image restoration, and automated classification algorithms for image analysis. It can be widely applied in advanced manufacturing and intelligent medical fields such as deep image processing and image recognition, with its accuracy and standardization rates reaching internationally leading levels.

Full name of the enterprise:Zhejiang Zhida Pharmaceutical Co., Ltd.

Roadshow Project Name:Commercialization and Internationalization of Nanomedicine Delivery Systems

Project Introduction for Roadshow:ZhiDa Pharmaceuticals is a pharmaceutical company focused on innovation in drug delivery systems, dedicated to the technology and industrialization of nanomedicine delivery platforms. Utilizing its unique liposome drug delivery technology platform, the company has successfully developed the first high-end generic nanoliposome delivery system drug—Doxorubicin Liposome Injection (ZhiSai), which has been approved and deemed to have passed the generic drug consistency evaluation. ZhiDa Pharmaceuticals possesses several core technologies, including a nanoliposome drug delivery platform and an albumin nanoparticle drug delivery platform, and has a GMP-certified nanoliposome drug production line. In the future, ZhiDa Pharmaceuticals will continue to focus on the research, development, and translation of drugs based on novel drug carrier systems (NDDS), providing more precise and efficient treatment options for patients and contributing to the advancement of China's advanced pharmaceutical manufacturing.

Full name of the enterprise:Saiyuan Biotechnology (Hangzhou) Co., Ltd.

Roadshow Project Name:Application of Next-Generation CAR Macrophages in Immune Cell Therapy for Solid Tumors

Project Introduction for Roadshow:CellOrigin is committed to the research and clinical transformation of engineered innate immune cells, such as CAR-iMac. The company utilizes technologies like gene editing and synthetic biology to obtain engineered immune cells derived from peripheral blood or iPSCs, with several core patents already authorized domestically and internationally.

CellOrigin Bio fully leverages the characteristics of macrophages, which can easily penetrate the tumor microenvironment (TME) and survive effectively, and is actively developing CAR-iMac products primarily targeting various types of recurrent/refractory solid tumors. The company has successfully established a clinical-grade iPSC cell bank, independently developed a scalable production process for CAR-iMac cells, and built a complete GMP quality system along with corresponding quality testing methods. In collaboration with multiple hospitals, the company is advancing the application for an IND registration certificate. A new round of financing is also underway.

Full name of the group:United Medical Alliance for Health Management (Shanghai) Co., Ltd.

Roadshow Project Name:Zhongzhongji Medical - A Chain Specialty Clinic for Spine with Scoliosis as its Feature

Roadshow Project Introduction:United Medical Alliance Grand Health Management (Shanghai) Co., Ltd. is an investment and operation management enterprise focusing on the field of spinal health. With the vision of "building a comprehensive sharing platform for China's spinal health industry," it focuses on investment and operation of spinal chain clinics, research and sales of spinal rehabilitation aids, development of digital medical products, and training in spinal rehabilitation technology to provide modern intelligent health management services for patients with spinal pain worldwide. Zheng Zhongji Chain Medical Services, under the United Medical Alliance Grand Health Group, was established in 2018 as a national chain medical service brand. With the mission of "supporting the youth and straightening the backbone of the nation," it innovatively integrates orthopedics, chiropractic neurology, sports rehabilitation, and physical therapy. By introducing rehabilitation technologies such as the German Schroth Scoliosis Correction Method and Czech SPS, it has formed a comprehensive treatment system that blends Eastern and Western approaches and combines medicine with physical fitness. The company specializes in non-surgical correction of adolescent scoliosis, adult spinal-related diseases, bone joint pain treatment, and prevention and intervention of spinal sub-health. Headquartered in Shanghai, it extends its reach nationwide and has already established more than ten medical institutions in cities such as Shanghai, Hangzhou, Shenzhen, Hefei, and Ningbo.